Animace načítání

Stránka se připravuje...


Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Právní předpis byl sestaven k datu 18.03.2026.

Zobrazené znění právního předpisu je účinné od 28.01.2025.


Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx mění x xxxxxxxx sdělení Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx I - Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy proti xxxxxxx xx xxxxxx.

X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu o xxxxxxx změn Přílohy X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx I xxxxxxxxx x platnost x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2024, pro Xxxxxx xxxxxxxxx xxxxxxxxx x platnost dne 18. června 2024 x nahradilo Xxxxxxx X xxx rok 2023, platnou od 1. ledna 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx vyhlášena xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 x její xxxxxxx do xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Ph.D., LL.M., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx a xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx jazyka

Úvod

Seznam zakázaných xxxxx x xxxxx xxxxxxx je xxxxxxx Xxxxxxxxxxx standard v xxxxx Světového antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx po rozsáhlém xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.

Oficiální xxxx Xxxxxxx zakázaných xxxxx x xxxxx xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx jsou uvedeny xxxxxxx xxxxx xxxxxxxxx x tomto Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx soutěži

Pokud XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx před xxxxxxx (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx zúčastnit, xx do xxxxx Xxxxxxx x xxxxxxx xxxxxx Vzorku.

Zakázané stále

To xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, xxx je xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx účely xxxxxxxx článku 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx. Žádná Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx metodou, pokud xxxx x Xxxxxxx xxxxxxxxx označena xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx a Xxxxxxxxxx xxxxxx uvedené x xxxxxx 4.2.2 xx neměly být xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx dopingové xxxxx nebo xxxxxx. Xxx xxxxx o xxxxx a xxxxxx, xxxxx Xxxxxxxxx pravděpodobně xxxx xxxx xxxxxx x xxxxxx xxxxx xxx ke zlepšení xxxxxxxxxxx výkonu.“

Návykové látky

Podle xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx jsou xxxx xxxxxx označeny x xxxxxx xxxxxx častého xxxxxxxxxx xx společnosti xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxx xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 NESCHVÁLENÉ XXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Xxxxxxx a xxxxx xxxx x xxxxxxxx xxxx schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx xxxxxxx u xxxx (např. xxxxxx x xxxxxxxxxxxxx nebo xxxxxxxxx vývoji xxxx xxxxxxx vývoj xxx xxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx zakázána xxxxx.

Xxxx xxxxx xxxxxxxx mnoho xxxxxxx látek, mimo xxxx BPC-157, 2,4-dinitrofenol (XXX) a xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Tirasemtiv).

S1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:

1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)

&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;

&xxxx;•&xxxx;

xxxxxxxxxx

1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion)

 •

furazabol (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)

1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxx

1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxxx

1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)

 •

mesterolon

4-androstenediol (androst-4-en-3ß, 17ß-xxxx)

&xxxx;•

xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)

4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)

&xxxx;•

xxxxxxxxx

5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx

7ɑ-xxxxxxx-XXXX

&xxxx;•

xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)

7ß-xxxxxxx-XXXX

&xxxx;•

xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

7-xxxx-XXXX

&xxxx;•

xxxxxxxxxxxxxx

11ß-xxxxx-19-xxxxxxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)

17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)

19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-diol)

 •

metyltestosteron

19-norandrostenedion (xxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)

Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)

&xxxx;•

xxxxxxxxx (19-xxxxxxxxxxxxxx)

xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol)

 •

norboleton

androstenedion (xxxxxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx

xxxxxxxx

&xxxx;•

xxxxxxxx

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxx

xxxxxxxxx

&xxxx;•

xxxxxxxxxx

xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)

&xxxx;•

xxxxxxxxx (dehydroepiandrosteron, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)

xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)

&xxxx;•

xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol)

 •

quinbolon

dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxxx

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)

 •

testosteron

epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)

xxxxxxxxxxxxxx

&xxxx;•

xxxxxxx

xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)

&xxxx;•

xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)

xxxxxxxxxxxxxx

&xxxx;•

xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx včetně:

Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 a XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX A XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. ERYTROPOETINY (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx XXX, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx a xxxxxx sloučeniny, xxxx. XXXX-530, peginesatid.

S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxx. xxxxxx; daprodustat (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (AKB-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (TGF-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx receptoru, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX HORMONY X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x mužů, xxxx xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (CG),

• xxxxxxxxxxxx xxxxxx (LH),

• hormon xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) x jeho xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx analogy x xxxxxxxxx, xxxx xxxx včetně:

• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx xxxxxxxxx xxxxxxx, např. XXX-9604 x hGH 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx jiné xxxxxx:

• hormon xxxxxxxxxx xxxxxxx hormon (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx hormonu (XXX) x xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx uvolňující GH (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx růstové xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x jeho analogy

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)

• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. TB-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx faktory xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxx látky.

Všichni selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx jiné xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin x xxxxxxxxxx dávkách, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx jakékoliv dávce;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;

• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: maximálně 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost salbutamolu x xxxx x xxxxxxxx xxxxxx než 1000 xx/xx xxxx xxxxxxxxxxx x množství xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že abnormální xxxxxxxx byl xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx xx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxxx látky ve xxxxxxx X4.1 x X4.2 jsou Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx do xxxx X4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx modulátory xxxx xxxxxxxx.

X4.1. INHIBITORY XXXXXXXX

Xxxx xxxx xxxxxx:

2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)

2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)

3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)

xxxxxxxxx

3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)

formestan

4-androsten-3,6,17 xxxxx (6-xxx)

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]

Xxxx jiné xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X

xxxxxxxxxx xxxxxxxxxx, např.:

konkurenty xxxxxxxxx xxxxxxxx XXX, xxxx.:

- xxxxx snižující xxxx xxxxxx xxxxxxx xxxxxxxxxx

- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. ACE-031)

- proteiny xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx)

xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx)

- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté peroxizomovými xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x xxxxxxxx Xxx-xxxɑ , xxxx. SR9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 DIURETIKA X XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Specifické xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, xxxx zakázány.

Mimo xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx etakrynová; furosemid; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a hydrochlorothiazid; xxxxxxxxx; triamteren;

• Xxxxxxx, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;

• Plazmatické expandéry xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;

• Desmopresin;

• Probenecid;

a xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

XXXXXXX

• drospirenon; xxxxxxxx; x lokální xxxxxxxxxxxxxx xxxxxxxx inhibitorů karboanhydrázy (xxxx. dorzolamid, brinzolamid);

• xxxxxxx podání xxxxxxxxxxx x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, katinu, efedrinu, xxxxxxxxxxxxx a pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx xxxx lokálního xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (AAF), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na xxxx xxxxx navíc x xx, která již xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx xxxx Specifické xxxxxx.

X1. XXXXXXXXXX S XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx xxxx opětovné xxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx z xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx do oběhového xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu xxxx xxxxxxx kyslíku.

Mimo xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx produkty, xxxx. xxxxxx xxxxxxxx na xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx doplňkového xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx intravaskulární manipulace x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX MANIPULACE

Zakázané xx xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx x podvod xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx odebraných při Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx a/nebo xxxxxx Xxxxxx, např. přidáním xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx než xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. GENOVÝ X BUNĚČNÝ XXXXXX

X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx technologie xxxxx xxxx, umlčování genů x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx zakázané látky x xxxx xxxxx xxxx Xxxxxxxxxx látky x xxxxxxxx xxxxx xxxxxxxxx v X6.X, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x metylendioxymetamfetamin (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x x-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

adrafinil

fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxx(x-)

xxxxxxxxx

x-xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx v xxxxx oddíle, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)

xxxxxxxxxxx

xxxxxxxxx

3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)

xxxxxxxxxxx

xxxxxxxxx (xxxxxxxxxxxxx)

4-xxxxxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxx

4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)

xxxxxxxxxx

xxxxxxxxxxx

4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin)

hydrafinil (xxxxxxxxx)

xxxxxxxxxxx x jeho xxxxxxxx

5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX)

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)

xxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxxxxxx

xxxxx1)

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxx a xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxxxxxx2)

xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxx

xxxxxxx3)

xxxxxxxxxxxx3)

xxxxxxxxxx

xxxxxxxxx (xxxxxxxxx)4)

xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx (metylendioxyamfetamin)

etylamfetamin

norfenefrin

tuaminoheptan

etilefrin

oktodrin (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky

VÝJIMKY

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx jejich xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx zařazená xx Xxxxxxxxxxxxxx xxxxxxxx 20245).

X7 NARKOTIKA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx xxxxx optických xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.

xxxxxxxxxxx

xxxxxxxx a xxxx xxxxxxxx

xxxxxx

xxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx (heroin)

metadon

oxykodon

tramadol

oxymorfon

S8 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané xxxxx v této xxxxx xxxx Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (THC)

Všechny xxxxxxxx x xxxxxxxxxx kanabinoidy xxxx xxxxxxxx, xxxx.

• x xxxxxx (hašiš, xxxxxxxxx) x konopných xxxxxxxxxx

• přírodní x xxxxxxxxxx tetrahydrokanabionoly (THC)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx podávány xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx cestou.

Mimo xxxx xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxxx acetonid

kortizon

hydrokortizon

deflazakort

metylprednisolon

POZNÁMKA

• Jiné xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, intranazálního, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx se používají x xxxxx výrobcem xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx indikací.

P1 BETA-BLOKÁTORY

ZAKÁZANÉ X XXXXXXXX SPORTECH

Všechny xxxxxxxx látky v xxxx třídě xxxx Xxxxxxxxxx látky.

Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx x kde xx to xxxxxxxx xxxxxxxx (*) x Xxxx soutěž.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx a xxxxxxxxx X-xxxxx / xxx xxx

• xxxxxxxxxxxx xxxxx (FIA)

• podvodní xxxxxx (CMAS)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx na terč

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (XXX)

• xxxx (XXX)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo jiné xxxxxx:

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

1) xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx xxx koncentraci x xxxx vyšší xxx 5 xxxxxxxxxx x 1 ml.

2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx koncentraci x xxxx vyšší xxx 150 xxxxxxxxxx x 1 xx.

3) xxxxxxx x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx x xxxx xxxxx než 10 mikrogramů x 1 ml.

4) epinefrin (xxxxxxxxx): není xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxx, oční, nebo xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol a xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx právních xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx